Karyopharm Therapeutics (KPTI) Change in Acquisitions & Divestments (2015 - 2025)

Karyopharm Therapeutics (KPTI) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $5.0 million in Q4 2025.

• Quarterly Change in Acquisitions & Divestments fell 69.23% year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.4 million (down 71.91% YoY) and the FY2025 annual result came in at $43.4 million, down 71.91% from the prior year.
• Change in Acquisitions & Divestments improved to $5.0 million in Q4 2025, from $4.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $69.0 million in Q1 2021 to a low of $4.8 million in Q3 2025.
• A 5-year average of $34.0 million and a median of $31.1 million in 2021 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 113.38% — and 2025, when it plunged 83.01%.
• Tracing KPTI's Change in Acquisitions & Divestments over 5 years: stood at $30.5 million in 2021, then increased by 4.34% to $31.8 million in 2022, then surged by 36.49% to $43.4 million in 2023, then tumbled by 62.56% to $16.2 million in 2024, then tumbled by 69.23% to $5.0 million in 2025.
• The last three Change in Acquisitions & Divestments figures came in at $5.0 million (Q4 2025), $4.8 million (Q3 2025), and $18.3 million (Q2 2025), per Business Quant data.